STOCK TITAN

Verona Pharma Plc - VRNA STOCK NEWS

Welcome to our dedicated news page for Verona Pharma Plc (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verona Pharma Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verona Pharma Plc's position in the market.

Rhea-AI Summary
Verona Pharma plc (VRNA) appoints Mr. Andrew Fisher as General Counsel, bringing extensive legal and strategic experience to the company. Additionally, Ms. Claire Poll retires as General Counsel. Verona Pharma prepares for US commercialization of ensifentrine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
Rhea-AI Summary
Verona Pharma plc announces strong financial results for Q4 and full year 2023, with preparations advancing for the potential launch of ensifentrine for COPD treatment in the US. The FDA has set a PDUFA target action date of June 26, 2024, for ensifentrine, with no advisory committee meeting planned. Verona Pharma secured a $400 million debt financing facility to support commercialization efforts through at least 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Verona Pharma plc (VRNA) will report its Q4 and full-year 2023 financial results on February 29, 2024. An investment community conference call will follow to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
conferences earnings
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) has announced the appointment of Mr. Michael Austwick as a Non-Executive Director, bringing extensive experience in the biopharmaceutical industry and respiratory expertise. The company also reported the resignation of Mr. Rishi Gupta as a Non-Executive Director. Verona Pharma is preparing for the US launch of ensifentrine, pending approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
conferences
-
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) strengthens financial flexibility with a $400 million debt financing facility provided by Oxford Finance LLC and Hercules Capital, Inc. The facility will support the planned commercial launch of ensifentrine, Verona Pharma’s first-in-class product candidate, under review by the US Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
none
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) CEO Wins 'Executive of the Year 2023' at SCRIP Awards for Leadership in COPD Treatment. David Zaccardelli, Pharm. D., expressed gratitude to the Verona Pharma team for their efforts in bringing their first-in-class treatment to COPD patients worldwide. Ensifentrine is under review by the US FDA for COPD maintenance treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
none
-
Rhea-AI Summary
Verona Pharma plc (VRNA) announces senior management will present a company overview at upcoming healthcare conferences in November 2023. The conferences include Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and 6th Annual Evercore ISI HealthCONx Conference. Webcasts of each presentation will be available on the Company’s website. Contact information for investor and media inquiries is provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
-
Rhea-AI Summary
Verona Pharma announces FDA acceptance of NDA filing for ensifentrine for COPD maintenance treatment. PDUFA target action date set for June 26, 2024. Commercial launch preparations underway. Company presents positive Phase 3 trial results and launches disease awareness campaign.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
Rhea-AI Summary
Verona Pharma to report Q3 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences earnings
Verona Pharma Plc

Nasdaq:VRNA

VRNA Rankings

VRNA Stock Data

1.29B
440.24M
4.28%
85.6%
8.1%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United Kingdom
3 More London Place

About VRNA

verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin